CTLA‐4 inhibitor ipilimumab alone showed no significant effect on lung cancer [21]. Neoadjuvant immunotherapy in patients with resectable NSCLC resulted in a 45% major pathology response (MPR) and 40% downstaging. Here, CTLA4 is linked to non-small cell lung carcinoma.